Beta Bionics, Inc. (BBNX) Price & Analysis

Compare

21 Followers

BBNX Stock Chart & Stats

Day’s Range― - ―

52-Week Range$8.89 - $24.50

Previous CloseN/A

VolumeN/A

Average Volume (3M)578.53K

Market Cap

$660.75M

Enterprise Value$389.82M

Total Cash (Recent Filing)$249.72M

Total Debt (Recent Filing)$6.69M

Price to Earnings (P/E)―

Beta1.38

Next Earnings

Nov 05, 2025

EPS Estimate

-0.42

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.39

Shares Outstanding43,470,123

10 Day Avg. Volume853,567

30 Day Avg. Volume578,532

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market Cap0.59

Enterprise Value/Revenue5.00

Enterprise Value/Gross Profit9.26

Enterprise Value/Ebitda-5.89

Forecast

1Y Price Target

$22.21

Price Target Upside40.48% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering7

Bulls Say, Bears Say

Bulls Say

Commercial StrategyBBNX's continued execution of its commercial strategy, particularly in pharmacy which continues to scale quicker than expected.

Market PenetrationBBNX now has formulary agreements in place with every major US PBM, which should support continued penetration of the higher revenue, higher margin pharmacy channel.

Bears Say

Industry ChallengesFourth-to-market players can be tricky in med tech.

Market CompetitionRisks include the inability to gain market share against larger players and potential delays to patch timing.

Beta Bionics, Inc. News

Beta Bionics price target raised to $21 from $18 at Truist

Truist analyst Richard Newitter raised the firm’s price target on Beta Bionics (BBNX) to $21 from $18 and...

10d ago

BBNX

Beta Bionics price target raised to $17 from $15 at Baird

Baird raised the firm’s price target on Beta Bionics (BBNX) to $17 from $15 and keeps a Neutral...

10d ago

BBNX

Beta Bionics reports Q2 EPS (39c), consensus (47c)

Reports Q2 revenue $23.24M, consensus $19.69M. The company said, “Installed customer base of 24,085 users, up 200% compared...

10d ago

BBNX

Beta Bionics raises FY25 revenue view to $88M-$93M from $82M-$87M

Consensus $87.74M. Sees FY25 gross margin 52%-55%. Published first on TheFly – the ultimate source for real-time, market-moving...

10d ago

BBNX

Beta Bionics participates in a conference call with Lake Street

Conference call with management will be held on July 24 at 3 pm hosted by Lake Street.Webcast Link...

26d ago

BBNX

Beta Bionics Reports Record Growth in Earnings Call

Beta Bionics, Inc. (($BBNX)) has held its Q2 earnings call. Read on for the main highlights of the...

8d ago

BBNX

Beta Bionics, Inc.: Strong Commercial Execution and Promising Growth Prospects Drive Buy Rating

Analyst Mike Kratky of Leerink Partners reiterated a Buy rating on Beta Bionics, Inc., boosting the price target...

9d ago

BBNX

Beta Bionics Reports Strong Q2 Growth and Raises Guidance

Beta Bionics, Inc. ( ($BBNX) ) has released its Q2 earnings. Here is a breakdown of the information...

10d ago

BBNX

Wells says CBP proposal for CGMs expected, insulin pumps inclusion ‘a surprise’

Wells Fargo analyst Larry Biegelsen notes that CMS released its proposed CY26 Home Health Prospective Payment System rule,...

1M ago

ABT

MDT

Beta Bionics Unveils Promising iLet Bionic Pancreas Data

An announcement from Beta Bionics, Inc. ( ($BBNX) ) is now available. On June 22, 2025, Beta Bionics,...

2M ago

BBNX

Beta Bionics, Inc.: Strategic Growth and Market Penetration with iLet Infusion Pump

Beta Bionics, Inc. (BBNX) has received a new Buy rating, initiated by Truist Financial analyst, Richard Newitter. Richard...

2M ago

BBNX

Beta Bionics initiated with a Buy at Truist

Truist initiated coverage of Beta Bionics (BBNX) with a Buy rating and $26 price target Beta Bionics is...

2M ago

BBNX

Beta Bionics assumed with a Buy at Lake Street

Lake Street assumed coverage of Beta Bionics (BBNX) with a Buy rating and $30 price target The company...

2M ago

BBNX

Beta Bionics initiated with an Outperform at Wolfe Research

Wolfe Research last night initiated coverage of Beta Bionics (BBNX) with an Outperform rating and $20 price target...

2M ago

BBNX

BBNX FAQ

What was Beta Bionics, Inc.’s price range in the past 12 months?

Beta Bionics, Inc. lowest stock price was $8.89 and its highest was $24.50 in the past 12 months.

What is Beta Bionics, Inc.’s market cap?

Beta Bionics, Inc.’s market cap is $660.75M.

When is Beta Bionics, Inc.’s upcoming earnings report date?

Beta Bionics, Inc.’s upcoming earnings report date is Nov 05, 2025 which is in 88 days.

How were Beta Bionics, Inc.’s earnings last quarter?

Beta Bionics, Inc. released its earnings results on Jul 29, 2025. The company reported -$0.39 earnings per share for the quarter, beating the consensus estimate of -$0.459 by $0.069.

Is Beta Bionics, Inc. overvalued?

According to Wall Street analysts Beta Bionics, Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Beta Bionics, Inc. pay dividends?

Beta Bionics, Inc. does not currently pay dividends.

What is Beta Bionics, Inc.’s EPS estimate?

Beta Bionics, Inc.’s EPS estimate is -0.42.

How many shares outstanding does Beta Bionics, Inc. have?

Beta Bionics, Inc. has 43,470,123 shares outstanding.

What happened to Beta Bionics, Inc.’s price movement after its last earnings report?

Beta Bionics, Inc. reported an EPS of -$0.39 in its last earnings report, beating expectations of -$0.459. Following the earnings report the stock price went up 14.325%.

Which hedge fund is a major shareholder of Beta Bionics, Inc.?

Currently, no hedge funds are holding shares in BBNX

Beta Bionics, Inc. Stock Smart Score

Neutral

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

35.99%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Beta Bionics, Inc.

Beta Bionics, Inc., a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes. It offers iLet Bionic Pancreas, an insulin delivery device for the treatment of type 1 diabetes in adults and children six years of age and older. The company is also developing Patch Pump, an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing; Bihormonal iLet, which combines automated delivery of insulin and glucagon; and iLet to treat people with insulin-dependent type-2 diabetes. It has collaboration and license agreement with Xeris Pharmaceuticals, Inc. (Xeris) to develop and commercialize a pump-compatible glucagon formulation; and development and commercialization agreement with Abbott Diabetes Care Inc. to develop and commercialize an automated insulin delivery system. The company was incorporated in 2015 and is based in Irvine, California.

Beta Bionics, Inc. (BBNX) Earnings & Revenues

Historic Earnings Reports

BBNX Company Deck

BBNX Earnings Call

Q2 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call presented a strong quarterly performance with record revenue growth and a significant increase in new patient starts. The expansion of the pharmacy channel and improved gross margins are positive indicators. However, increased operating expenses and uncertainties around the CMS proposal present challenges. Overall, the positive aspects significantly outweigh the challenges.View all BBNX earnings summaries

BBNX Stock 12 Month Forecast

Average Price Target

$22.21

▲(40.48% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"10":"$10","31":"$31","15.25":"$15.25","20.5":"$20.5","25.75":"$25.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":30,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$30.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":22.21,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$22.21</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":17,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$17.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[10,15.25,20.5,25.75,31],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,16.4,17.446153846153845,18.49230769230769,19.538461538461537,20.584615384615383,21.63076923076923,22.676923076923075,23.723076923076924,24.769230769230766,25.815384615384616,26.86153846153846,27.907692307692308,28.953846153846154,{"y":30,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,16.4,16.846923076923076,17.293846153846154,17.74076923076923,18.187692307692306,18.634615384615383,19.08153846153846,19.52846153846154,19.975384615384616,20.42230769230769,20.869230769230768,21.316153846153846,21.763076923076923,{"y":22.21,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,16.4,16.446153846153845,16.49230769230769,16.538461538461537,16.584615384615383,16.63076923076923,16.676923076923075,16.723076923076924,16.76923076923077,16.815384615384616,16.861538461538462,16.907692307692308,16.953846153846154,{"y":17,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":23.81,"date":1725148800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":23.81,"date":1727740800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":23.81,"date":1730419200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":23.81,"date":1733011200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":23.81,"date":1735689600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":23.81,"date":1738368000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":23.81,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.97,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.24,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.14,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.69,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.94,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.4,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >